Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide for Adult Histiocyte Disorders
NCT02523040Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2015
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), histiocytic sarcoma (HS), sponsored by Dana-Farber Cancer Institute. Started Aug 2015; status: active, not recruiting.
02
Drugs
lenalidomide
03
Conditions
Langerhans cell histiocytosis (LCH)Erdheim-Chester disease (ECD)histiocytic sarcoma (HS)
Beyond the preview
Go deeper on NCT02523040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02523040.